Nimbus Therapeutics TYK2 program to be acquired by Takeda for $4B in upfront cash and up to $2B in potential commercial milestone payments Notable Dec 13 Written By Frances Benson https://www.nimbustx.com/2022/12/13/takeda-to-acquire-nimbus-therapeutics-highly-selective-allosteric-tyk2-inhibitor-to-address-multiple-immune-mediated-diseases/ 2022 Frances Benson
Nimbus Therapeutics TYK2 program to be acquired by Takeda for $4B in upfront cash and up to $2B in potential commercial milestone payments Notable Dec 13 Written By Frances Benson https://www.nimbustx.com/2022/12/13/takeda-to-acquire-nimbus-therapeutics-highly-selective-allosteric-tyk2-inhibitor-to-address-multiple-immune-mediated-diseases/ 2022 Frances Benson
